LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sensitive Method Detects Early Amyloidosis in Humans

By LabMedica International staff writers
Posted on 03 Apr 2016
Print article
Image: Luminescent conjugated oligothiophene, h-FTAA staining of tissue showing amyloid deposits, yellow red fluorescence (Photo courtesy of Linköping University).
Image: Luminescent conjugated oligothiophene, h-FTAA staining of tissue showing amyloid deposits, yellow red fluorescence (Photo courtesy of Linköping University).
The amyloidoses comprise a large group of diseases characterized by extracellular deposits in various tissues and organs. These deposits, termed “amyloid,” result from misfolding and/or partial unfolding of proteins followed by their ordered aggregation into amyloid fibrils with specific β-sheet conformation.

Diagnosis of amyloidosis requires a tissue biopsy and the biopsy is assessed for evidence of characteristic amyloid deposits. The most useful stain in the diagnosis of amyloid is Congo red, which, combined with polarized light, makes the amyloid proteins appear apple-green on microscopy.

Scientists at the Linköping University (Sweden) and their colleagues identified patients diagnosed with amyloidosis in the amyloid collection of Uppsala Biobank (Sweden). They chose 53 paraffin-embedded tissue blocks with noticeable amyloid deposits from 50 patients. A second set of amyloid specimens was retrieved and included 61 paraffin-embedded tissue blocks with conspicuous amyloid deposits from 61 patients, including 24 women and 37 men. A control set of eight tissue samples were retrieved from five patients aged 69 to 78 years, comprising heart, liver and kidney. Tissues from a control group of 27, included kidney, stomach, heart, lung, ovary, pancreas and duodenum, which showed no interstitial amyloid deposits as assessed by Congo red staining and polarization microscopy.

Archived paraffin-embedded formalin fixed sections were processed and stained with a luminescent conjugated oligothiophene, h-FTAA, that stains rapidly and with high sensitivity and selectivity detects amyloid deposits in verified clinical samples from systemic amyloidosis patients with AA, AL and ATTR types; as well as in tissues laden with localized amyloidosis of AANF, AIAPP and ASem1 type. For the archived paraffin-embedded formalin fixed tissue specimens as well as dried fine needle aspired (FNA) abdominal fat biopsies it was found that a 1:5,000 staining solution corresponding to 0.2 mg/L of h-FTAA was optimal. Fluorescence images and spectra were recorded with a Leica DM6000 B fluorescence microscope (Leica Microsystems; Wetzlar, Germany).

The probe h-FTAA emitted yellow red fluorescence on binding to amyloid deposits, whereas no apparent staining was observed in surrounding tissue. The only functional structure stained with h-FTAA showing the amyloidotypic fluorescence spectrum was Paneth cell granules in intestine. Screening of 114 amyloid containing tissues derived from 107 verified (Congo red birefringence and/or immunohistochemistry) amyloidosis patients revealed complete correlation between h-FTAA and Congo red fluorescence. The majority of Congo red negative control cases (27 of 32, 85% specificity) were negative with h-FTAA. Small Congo red negative aggregates in kidney, liver, pancreas and duodenum were found by h-FTAA fluorescence in five control patients aged 72–83 years suffering from diverse diseases.

The authors concluded that conclude that h-FTAA is a fluorescent hypersensitive, rapid and powerful tool for identifying amyloid deposits in tissue sections. Use of h-FTAA can be exploited as a rapid complementary technique for accurate detection of amyloid in routine surgical pathology settings. The results also implicate the potential of the technique for detection of prodromal amyloidosis as well as for discovery of new amyloid-like protein aggregates in humans. The study was published on March 17, 2016, in Amyloid: The Journal of Protein Folding Disorders.

Related Links:

Linköping University
Leica Microsystems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more